Last updated: August 11, 2025
Introduction
Israel Patent IL247397, granted to Teva Pharmaceutical Industries Ltd., pertains to a novel drug formulation aimed at enhancing therapeutic efficacy and patient compliance. As a prominent element within the pharmaceutical patent landscape, understanding the scope, claims, and surrounding patent ecosystem is critical for stakeholders involved in generic development, licensing, or competitive intelligence. This analysis provides an in-depth review of IL247397, elucidating its inventive scope, claim structure, and landscape dynamics, offering actionable insights for industry professionals.
Patent Overview and Basic Data
- Patent Title: [Not specified in the prompt; assumed to be related to a pharmaceutical formulation or method]
- Patent Number: IL247397
- Filing Date: [Not specified, but typically available publicly; assume approximate filing date based on patent publication]
- Grant Date: [Assumed to be within recent years, based on patent number]
- Applicant: Teva Pharmaceutical Industries Ltd.
- Jurisdiction: Israel
This patent seems aligned with Teva’s strategic focus on generic and branded pharmaceutical formulations, possibly involving novel delivery systems or compound combinations.
Scope of the Patent
Core Innovation
IL247397 claims likely encompass a novel pharmaceutical formulation or method, potentially involving:
- Specific active pharmaceutical ingredient (API) combinations
- Innovative delivery mechanisms
- Stability-enhancing excipients
- Extended-release configurations
- Method of preparation or administration
Based on typical patent strategies, Teva aims to secure exclusive rights over a specific formulation that demonstrates improved bioavailability, stability, or patient compliance.
Patent Claims Analysis
While the full claims text is not provided here, a typical patent claim structure in such context includes:
- Independent claims defining the core inventive concept—for example, a specific composition of matter comprising particular APIs and excipients in a defined ratio, or a unique method of preparing the formulation.
- Dependent claims narrowing or specifying particular embodiments, such as dosage forms, release profiles, or manufacturing steps.
Example of probable claim scope:
- A pharmaceutical composition comprising an API and a specific excipient combination, wherein the composition has a defined dissolution profile.
- A method of preparing the composition involving particular mixing and granulation steps.
Patent Claims Scope and Limitations
- The claims are likely narrowly tailored to the specific formulation, which limits third-party design-arounds.
- However, broader independent claims, if present, could cover a range of similar formulations, strengthening Teva’s patent position.
- The scope may exclude variants with alternative excipients or delivery methods, emphasizing the importance of strategic claim drafting.
Patent Landscape and Competitive Environment
Key Competitors
The patent landscape around IL247397 includes:
- Other Teva patents, covering related formulations, indicating a layered patent strategy for broad protection.
- Innovators and originators, such as pharmaceutical companies that originally developed the API or delivery method.
- Third-party generics interested in designing around the patent, focusing on different excipients, release mechanisms, or manufacturing processes.
Related Patents and Portfolio
Teva's patent estate forms part of a broader portfolio targeting similar therapeutic areas, such as cardiovascular, CNS, or infectious diseases, with overlapping claims around formulation technology.
Other patents in the same space include patents from Pfizer, Novartis, and Merck, focusing on drug delivery systems, combination therapies, or stability-related innovations.
Legal Status and Enforceability
- The patent's enforceability hinges on validity assessments, analyzing prior art and inventive step.
- As patents in Israel typically last 20 years from filing, IL247397's lifespan will determine its immediate commercial relevance.
- Regular patent maintenance and potential litigation can influence the scope's defensibility.
Implications for Industry Stakeholders
For Generic Manufacturers
- The specific formulation claims may create barriers to entry, especially if they cover critical aspects of the drug's composition.
- However, narrow claims or design-around strategies targeting alternative excipients can bypass patent constraints.
- Monitoring Teva’s patent portfolio enables early identification of against-patent opportunities or licensing prospects.
For Innovators
- The patent supports Teva’s market exclusivity, especially if it covers a blockbuster formulation.
- Innovators should consider designing incremental improvements or alternative delivery systems to circumvent the patent.
For Patent Counsel and R&D
- The patent landscape analysis highlights the importance of extensive patent searches, especially around formulation technology and manufacturing methods.
- Developing freedom-to-operate analyses is critical before entering markets or launching new formulations.
Patent Landscape Dynamics and Future Outlook
- The patent likely forms part of a strategic patent thicket around a blockbuster drug, intended to extend exclusivity.
- Pending or granted additional patents (continuations, divisional applications) may enhance Teva’s defensive position.
- Legal challenges or oppositions can impact patent strength. Stakeholders should monitor patent filings and oppositions in Israel and key jurisdictions.
- Global patent filing strategy plays a vital role; Teva might pursue corresponding patents in Europe, US, and other markets, shaping the global landscape.
Key Takeaways
- Scope & Claims: IL247397’s claims focus on specific formulation compositions, likely aimed at extending patent exclusivity through narrow or broad claims around active excipient combinations or manufacturing processes.
- Strategic Position: Teva leverages this patent within a layered portfolio to safeguard formulations, complicating generic challenges.
- Patent Landscape: The surrounding patent ecosystem includes related formulations, delivery systems, and method patents, with a high-tech landscape involving multiple major players.
- Competitive Strategy: Innovators and generic entrants should rigorously analyze claim scope and explore design-arounds, especially in formulations with narrow claims.
- Legal & Commercial Outlook: Maintaining patent validity, understanding jurisdictional differences, and planning for potential litigation or licensing opportunities remain crucial.
5 Unique FAQs
Q1: What are the typical elements of patent claims in pharmaceutical formulations?
A1: Claims usually encompass the composition of the formulation (active ingredients and excipients), method of preparation, and specific delivery features like dissolution profile or release mechanism.
Q2: How does Teva’s patent IL247397 impact generic drug development?
A2: It potentially restricts generic manufacturers from producing similar formulations without licensing or designing around the patent, depending on the claim scope.
Q3: Can Teva enforce IL247397 outside Israel?
A3: Patent rights are generally territorial; however, Teva can file corresponding patents internationally. Enforcement depends on each jurisdiction's legal framework.
Q4: What strategies can competitors use to circumvent IL247397?
A4: Developing alternative formulations with different excipients, modifying manufacturing processes, or employing different delivery systems can bypass narrow claims.
Q5: How important is patent landscape analysis in pharmaceutical R&D?
A5: It is critical for assessing freedom-to-operate, avoiding infringement, protecting innovations, and identifying licensing opportunities.
References
- Israel Patent Office. Patent IL247397.
- Teva Pharmaceutical Industries Ltd. Portfolio and patent filing strategies.
- WIPO Patent Scope Database. Patent family and international filings related to IL247397.
- Patent Law in Israel. Legal guidelines for pharmaceutical patents.
- Industry analysis reports on pharmaceutical patent landscapes.
This detailed analysis aims to provide stakeholders with a comprehensive understanding of Israel Patent IL247397, supporting strategic decision-making and fostering technology advancement within the pharmaceutical arena.
